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ABSTRACT
Heat Shock Protein 27 Inhibition of Apoptosis in Human Breast Cancer Cells
by
Sindhu Padmanabhan
Dr. Stephen W. Carper, Examining Committee Chair 
Associate Professor o f Chemistry 
University o f Nevada, Las Vegas.
Cancer occurs when normal cells fail to die in response to various cell 
death signals. Normal eukaryotic cells exhibit two major forms o f cell death -  
Necrosis and Apoptosis. Apoptosis can be triggered in cells by various agents. 
Studies have shown that an elevated amount o f Hsp 27 protects cells from 
apoptosis induced by Sodium Butyrate. In this study, we treated estrogen receptor 
negative human breast cancer cells with apoptotic inducers such as Sodium 
Butyrate, Staurosporine, Vitamin E Succinate and Cycloheximide. The cells that 
constitutively expressed Hsp 27 had a higher growth in the presence of 
Cycloheximide and Vitamin E Succinate and also exhibited lesser apoptosis in the 
presence o f Sodium Butyrate and Staurosporine. This study demonstrates that 
Hsp 27 blocks cell death in breast cancer cells in the presence of certain cytotoxic 
drugs and the presence of this protein could serve as a marker for aggressive 
tumors.
iii
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CHAPTER 1
INTRODUCTION
Cancer
Cancer is a cellular disease characterized by the uncontrolled proliferation 
o f  cells leading to a local growth or tumor. Tumors are a caricature of the normal 
processes o f tissue renewal; they arise when the normal processes o f growth and 
differentiation go awry (1 ). In the normal cells that make up different parts o f our 
body, each cell has a definite function and a predictable life cycle. The growth 
and division o f normal cells is regulated by complex biochemical processes i.e., 
when a fully functional cell becomes senescent; it is shed and replaced by another 
cell that takes it’s place. A cancerous growth results when the regulation o f the 
cell cycle is upset and cells fail to respond to cell death signals.
A Faulty Regulation in Cancer Cells
Normal cells go through a specific number o f cell cycles after which they
die via a programmed cell death process known as apoptosis. Apoptosis is
distinct mode o f cell death occurring during the normal processes o f growth and
1
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development (2). It is responsible for deletion o f cells in normal tissues and is 
characterized by plasma membrane blebbing, condensation of cytoplasm and 
nucleus, and cellular fragmentation into membrane bound apoptotic bodies, which 
are phagocytysed by neighboring cells (2-6)(Figure 1, page 3). Biochemically, 
apoptosis is characterized by extensive endonucleolytic cleavage of double 
stranded DNA initially into large fragments o f 50-300 kilobases (6). The 
endonucleases then cleave the DNA at linker regions producing nucleosomes, 200 
base pairs o f DNA wound around a histone octamer (Figure 2, page 4). Cells can 
also die by necrosis, which involves swelling of cytoplasm and organelles 
followed by lysis o f  plasma membrane and random DNA fragmentation (2). An 
interesting feature o f apoptosis is that it can take place in isolated cells and unlike 
necrosis does not generate an inflammatory response. Apoptosis becomes 
important in a pathological context too, its deregulation leading to disease 
conditions such as cancer, neurodegeneration, ischemia, senescence and AIDS 
(7). Since apoptosis can be induced in cells, knowledge o f its mechanism can be 
a powerful tool in manipulating an apoptotic response in cancer and other 
diseases.
Apoptosis as a Biochemical Process
Apoptosis can be induced in cells by a variety o f  agents such as radiation 
(ionizing and UV), chemotherapeutic drugs, heat, hypoxia, glucocorticoids 
growth factor deprivation (2)(Figure 3, page 5). The exact mechanism(s)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1 Diagram illustrating the ultrastructural features o f apoptosis and 
necrosis. (Adapted &om Kerr, et al., Cancer, 73:2014, 1994)
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Linker DNA
DNA
Nucleosome HI Histone
Figure 2 Nucleosomes -  DNA associated with histones
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Triggers- Modulators Effectors Death
substrates
DNA damage, 
growth factor 
withdrawal, 
hypoxia, heat, 
glucocorticoids, 
etc.
p53,bcl-2,
kinases
ceramide
oncogenes
transcription
factors,
cytochrome c,
etc.
Cysteine proteases Lamins,
PARP,
fodrin,
etc.
Death
Figure 3 Common Apoptotic Pathway
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
by which these agents trigger apoptosis is not known but a family o f cysteine 
proteases (related to the interleukin-ip-converting enzyme (ICE)) become 
activated and execute apoptosis through specific cleavage o f substrates known as 
death substrates (8,9). Cysteine proteases belong to the family o f enzymes that 
degrade proteins. These proteases have a reactive cysteine at its active site 
(sulfhydryl site), which is responsible for catalyzing the cleavage o f peptide 
bonds.
The cysteine proteases, the major effectors of cell death, are present as 
inactive precursor polypeptides that are activated during the death process by 
cleavage at aspartic acid residues (9). These activated proteases cleave the death 
substrates at specific aspartic acid residues too, and hence are known as cysteine- 
aspases or Caspases (9,10,11). Recent work has shown that there are eleven 
mammalian caspases, which are divided into four classes on the basis o f their 
molecular homology (9). The activated caspases go on to cleave (a) DNA repair 
enzymes such as poly (ADP)-ribose polymerase and DNA dependent protein 
kinase, DNA-PK, thereby abolishing the DNA repair ability in cells (b) Structural 
proteins like lamin, leading to nuclear condensation, (c) Cytoskeletal proteins 
including actin, Gas-2 and fodrin, inducing cell shrinkage and membrane 
blebbing, (d) Small ribonucleoprotein Ul-70kDa, and (e) cell cycle mediators 
such as protein kinase C 8 and retinoblastoma protein Rb (11,12). Recently it has 
been reported that caspases are also responsible for activating a calcium 
dependent endonuclease, CAD, responsible for cleaving the DNA at the linker
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
regions (Figure 2, page 4) between nucleosomes by specifically cleaving and 
inactivating ICAD, the inhibitor of CAD (13). Hence turning on caspases acts as 
an irreversible signal for death by apoptosis.
Small Heat Shock Proteins and Apoptosis
Heat shock proteins (Hsp) are a unique family of highly conserved 
proteins produced by cells in response to environmental and pathophysiological 
stresses (14,15,16). The heat shock family of proteins is subdivided into four 
major classes based on the molecular weight of these proteins. They are Hsp 110, 
Hsp 90, Hsp 70 and Small heat shock proteins (sHsp) which include Hsp 27. 
Hsp’s are produced in response to environmental stresses such as heat shock, UV 
radiation, heavy metals and oxidants, physiological stimulants such as hormones, 
growth factors and cell cycle regulators, and pathophysiological conditions such 
as infections and glucose starvation (16). The main function o f the Hsp 90 and 
Hsp 70 class o f heat shock proteins is molecular chaperoning i.e., to preserve the 
proteins within the stressed cell in a folded state so that they are not denatured 
during the stress. In addition to the chaperoning function, these proteins are also 
involved in signal transduction and thermotolerance. Small heat shock proteins 
like Hsp 27 have been known to protect cells from oxidative stress, apoptosis and 
chemotherapeutic drugs (4,5,17).
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Hsp 27 and Breast Cancer
In normal breast tissue, the expression o f Hsp 27 is very low whereas it is 
present in very high amounts in human breast tumor cells (18). The presence of 
this protein is a prognostic marker for more aggressive tumors and indicates 
shortened disease free survival and increased resistance to chemotherapeutic 
drugs (19). Hsp 27 is an estrogen responsive protein. Mammary carcinoma cells 
having receptors for estrogen (ER^) and also expressing Hsp 27 can be sensitized 
to chemotherapeutic drugs by treating them with estrogen antagonists. Estrogen 
antagonists are structurally similar to estrogen and bind to the estrogen receptor. 
The antagonist binding inhibits estrogen from binding to its receptor, decreasing 
the proliferative effects caused by the binding o f estrogen to its receptor. The 
presence o f Hsp 27 in ER^ tumors is believed to increase the rate o f proliferation 
o f these cancerous cells (20). However we have seen Hsp 27 protect estrogen 
receptor negative (ER ) breast cancer cells from cytotoxic drugs and previous
work has shown that these ER cells can also be sensitized to doxorubicin, a
chemotherapeutic drug, by the estrogen antagonist toremifene (21). The exact 
mechanism by which Hsp 27 confers protection to tumor cells against 
chemotherapeutic drugs is still unclear.
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Significance o f  the Study
The main goal o f this work is to understand the role o f Hsp 27 in ER' 
breast cancer cells. The presence o f Hsp 27 in ER' breast cancer cells, as shown 
by our study protects these cells from various cytotoxic drugs. The exact 
mechanism by which Hsp 27 confers protection is not known, but its ability to do 
so at various points in the apoptotic pathway leads us to believe that it is acting 
downstream to these inducers.
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CHAPTER 2 
MATERIALS AND METHODS 
Cell Lines
The cell lines used in this study are derived from the estrogen receptor 
negative human breast cancer cells MBA-MD-231 by transfection with the 
constitutive expression vector pP27 (DB 46 and DB 26) or the control vector 
pHpApr-I-neo (DC 4 and DC 7) (21). Stable transfected cell lines were isolated 
and grown in Minimal Essential Media (MEM) (Gibco BRL), supplemented with 
10% fetal bovine serum, 25 mM HEPES buffer, 100 lU penicillin/ml, 1 OOpg/ml 
streptomycin, 2mM L-glutamine (Biowhittaker Inc.), and 600 pg/ml G418 sulfate
(Gibco BRL). All cultures were maintained at 37°C in humidified incubators with 
5% CÜ2 : 95% air. Twenty-four hours prior to an experiment, cells were washed 
and resuspended in supplemented MEM, lacking G418.
Cytotoxic Drugs
Sodium Butyrate, Staurosporine, Vitamin E Succinate and Cycloheximide
10
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were used in this study because o f  their reported capacity to act as apoptotic 
inducers (25-37). Growth inhibition and apoptosis induced by each drug was 
studied using MTT assay and enzyme linked immuno absorbent assay (ELISA) 
respectively (described in detail in separate sections). The drug treatment (i.e. the 
incubation time with the drug) and concentration of the drug varied with the drug 
used.
Sodium Butyrate
Sodium Butyrate (Sigma Chemical Co.) was prepared in deionized water 
(lOOmM). Appropriate concentrations o f the drug was added to Hsp 27 
expressing and control transfected cells, 24 hours after the cells were plated in a 
96 well plate (this incubation is done to let the cells attach to the plate). Growth 
inhibition was studied 24h and 48h after incubation with the drug. Apoptosis was 
measured 24h after incubation with the drug.
Staurosporine
Staurosporine (Sigma Chemical Co.) was prepared in DMSO (100 pM). 
Appropriate concentrations o f the drug was added to Hsp 27 expressing and 
control transfected cells, 24 hours after the cells were plated in a 96 well plate. 
Growth inhibition and apoptosis was studied 24h after incubation with the drug.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Vitamin E Succinate
Vitamin E Succinate (Sigma Chemical Co.) was prepared in 100% ethanol 
(5mM-15mM). Succinic acid (Sigma Chemical Co.) prepared in ethanol 
(1 mg/ml) was used as control. Appropriate concentrations o f the drug was added 
to Hsp 27 expressing and control transfected cells, 24 hours after the cells were 
plated in a 96 well plate. Growth inhibition was studied at 48h and 65h.
Cycloheximide
Cycloheximide (Sigma Chemical Co.) was prepared in 100% ethanol 
(10mM-40mM). Appropriate concentrations o f the drug was added to Hsp 27 
expressing and control transfected cells, 24 hours after the cells were plated in a 
96 well plate. Various concentrations o f Cycloheximide was added at the end of 
the incubation period and reincubated for 2h. At the end o f the incubation period 
with the drug, 200pl media was removed and 200 pi of fresh media was added to 
wells and the plate was incubated at 37°C. Growth inhibition was measured 24h- 
65h later.
Growth Assay
The growth o f the control transfected (DC 4 and DC 7) and Hsp27 
expressing cell lines (DB46 and DB26) in the presence o f cytotoxic drugs was 
measured using MTT (Sigma Chemical Co.) dye uptake procedure. The MTT
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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assay is a quantitative colorimetric assay that is rapid and does not involve the use 
of any radioisotopes (22).
Br©
■CH3
CH3
■CH3
MTT FORMAZAN
Figure 4 Reduction o f MTT to Formazan
MTT, (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), is a water 
soluble tétrazolium salt yielding a pale yellow solution in media or saline 
solutions lacking phenol red. The mitochondrial dehydrogenases o f living cells 
take up MTT and metabolize it to formazan, an insoluble purple product (Figure 
4).
This conversion takes place in the inner mitochondrial membrane by the 
enzymes o f  the electron transfer chain (23). In the presence o f MTT, this chain is 
disrupted and, the electrons are accepted by MTT, which undergoes reduction to 
formazan (Figure 5). The formazan formed is solubilized using acid isopropanol 
and measured spectrophotometrically using a plate reader at 570nm. The optical
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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density directly corresponds to activity o f  living cells relative to the control 
(untreated cells).
Succinate^^^^
FADH2 
Succinate-CoQ Reductase
C y tcl 
CoQ-Cytcl Reductase
->  MTT
-►MTT
C ytc
Cyt a/a3 
Cyt c oxidase
OXYGEN
Figure 5 Points of Interaction o f MTT with the Electron Transport Chain
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Experimental Procedure
About 1 x 1 0 *  cells/200pl o f culture medium were seeded into wells o f a 
96 well plate and incubated at 37°C for 24h. After 24 h, the medium was changed 
and appropriate cultures were treated with various cytotoxic drugs and incubated 
for 24-48h. At the end o f the incubation period, 20 pi o f  MTT (5mg/ml) was 
added and the plate was wrapped in aluminum foil and incubated at 37°C for 4h. 
After the incubation period, 150 pi o f the media was removed and 150 pi of 
isopropyl alcohol:IN HCl (98:4) was added and the absorbance determined at 
570nm using a microplate reader (Dynatech MR 5000). Results are presented as 
a percentage o f the control.
Apoptosis Assay
Apoptosis was quantitated using an enzyme linked immunosorbent assay 
(Boehringer Mannheim), which measures the cytoplasmic histone-bound DNA 
fragments (mono and oligonucleosomes) generated during apoptotic DNA 
fragmentation (Figure 6, page IT). The presence o f  these fragments in the 
cytoplasm is a characteristic of apoptosis and is a result o f endogenous 
endonucleases being activated by the proteolytic cascade. Antibodies directed at 
the DNA and histones in this “sandwich” assay, quantitatively determines 
apoptotic death induced by the cytotoxic drug relative to the control (untreated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cells). The two antibodies used in this assay are (1) Anti-histone antibody that 
targets the histone and (2) Anti-DNA-peroxidase that targets the DNA. The 
amount of these fragments present in the cytoplasm i.e., the amount o f peroxidase 
in the immunocomplex is determined photometrically by conjugation with ABTS 
(2,2’-azino-di-[3-ethylbenzthiazolinesulfonate(6)]) as a substrate. The specificity 
o f the antibodies to histone and DNA of the nucleosomes was not studied here, as 
we were interested in comparing the apoptosis induced in the Hsp 27 expressing 
cell lines to the control transfected cell line.
Experimental Procedure
Cells were plated (1 x 10*cells/200 pi) into wells o f a 96-well plate. After 
desired treatment, cytoplasmic extracts were made from both floating and 
attached cells, according to manufacturer’s protocol. Briefly, drug treated cells 
and untreated controls were lysed using a lysis buffer and centrifuged at 1000 
r.p.m. for 10 minutes. Control and drug-treated cell extracts were equalized on 
the basis o f equal cell number. The wells were first coated with anti-histone 
antibody, loaded with cytoplasmic extracts (centrifugate) and followed by 
incubation with anti-DNA second antibody conjugated with peroxidase. The 
ELISA was developed with peroxidase substrate, and the absorbance at 405 nm 
was measured using microplate autoreader (Dynatech MR5000).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
17
Anti histone 
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Figure 6 Double sandwich ELISA: Test Principle
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CHAPTER 3
RESULTS
Growth Inhibition of Breast Cancer Cells in the Presence o f Sodium Butyrate
- Sodium butyrate, a short chain fatty acid, is produced in the colon by the 
fermentation o f dietary fiber (24). Sodium butyrate and other short chain fatty 
acids (SCFA) have been known to induce growth arrest and promote apoptosis in 
many cell types including breast cancer cells (25-30). Sodium butyrate is non­
toxic and hence can be used for therapeutic purposes. In this study, the effect of 
sodium butyrate on the growth of breast cancer cells expressing Hsp 27 (DB 46 
and DB 26) was investigated and compared to their control transfected 
counterparts which do not express Hsp 27(DC 4 and DC 7). All cell lines were 
treated continuously with various concentrations o f sodium butyrate for 24 h or 48 
h. It has been reported that sodium butyrate causes growth arrest in the first 48 h, 
continuous treatment beyond this point led to little additional reduction in cell 
survival (26). The growth inhibition was measured using the MTT assay as 
described in Materials and Methods. As shown in Figure 7, (page 25), DC 4 cells 
were more sensitive to sodium butyrate at 48 h (46% growth at the highest
concentration o f butyrate) than DB 46 cells (54% growth at the highest
18
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concentration o f butyrate). These results are from a single experiment performed 
in triplicate. The experiment was repeated with DB 26 and DC 7 cells (Figure 8, 
page 26). In this case however, the growth o f Hsp27 expressing cells (DB 26) 
was not significantly higher than control transfected cells (DC 7) The validity o f 
the results were tested by using a t-test (Appendix). The error bars correspond to 
percentage deviation from the mean. At 24 h, however, the growth inhibition by 
butyrate was lower, and any differences between the cell lines were not 
statistically significant (Figure 9,page27  and Figure 10, page 28).
Apoptosis Induced by Sodium Butyrate
The ability o f Sodium Butyrate to induce apoptosis in our cell lines was 
studied using the enzyme linked immunosorbent assay (ELISA) as described in 
Materials and Methods. As shown in Figure 11 (page 29), Sodium Butyrate 
treatment o f DB 46 and DC 4 for 20 hours stimulated apoptosis in a dose 
dependent manner. The addition o f 10 mM Sodium Butyrate was able to increase 
the rate o f apoptosis in the control transfected cell line (DC 4) by almost 6.5 fold 
while in Hsp27 expressing cell line apoptosis was increased only 2 fold. These 
results are from a single experiment performed in triplicate. DB 26 cells however 
did not exhibit a dramatic resistance to butyrate.(Figure 12, page 30). These cells 
exhibited higher apoptosis in the presence o f 3mM Sodium Butyrate (5.0 fold 
increase in apoptosis) than the DB 46 cells (2.0 fold increase in apoptosis with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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respect to control). The differences in the Hsp 27 expressing cell lines (i.e., in 
their response to butyrate) may be due to clonogenic variations (i.e., the exact 
amount o f the protein present in different clones may be different).
Growth Inhibition by Staurosporine
Staurosporine, a microbial alkaloid induces its anti-cancer activity by the 
inhibition o f protein kinase C (31). Protein kinases are a group o f enzymes that 
catalyze the phosphorylation o f target proteins and regulate protein activity. 
Protein kinase C, a calcium dependent protein kinase, phosphorylates proteins at 
their serine and threonine residues. Diacylglycerol and tumor promoters such as 
phorbol esters activate this enzyme. Phorbol esters are structurally similar to 
diacylglycerol but are not easily metabolized. Since protein kinase C has been 
implicated in cellular proliferation (32), a persistent activation o f this enzyme by 
phorbol esters leads to the formation o f tumors. Staurosporine is a potent protein 
kinase C inhibitor (31) and induces growth arrest and apoptosis in a variety o f cell 
lines (33-35).
To determine whether Hsp 27 could offset the anti-proliferative and 
apoptotic potential of Staurosporine, we treated Hsp 27 expressing and control 
transfected breast cancer cells with micromolar amounts o f  Staurosporine for a 
period o f 24h. Our results indicate that at the highest concentration (5pM), 
Staurosporine had 93%-96% inhibition o f growth, as studied by the MTT assay.
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The Hsp 27 expressing cell lines did not have a higher tolerance for the drug 
when compared to the control transfected cell lines. Any differences seen 
between the cell lines were not statistically significant (Figure 13, page 31 and 
Figure 14, page 32). Each experiment was performed in triplicate and the error 
bars represent the percent deviation from the mean.
Induction o f  Apoptosis by Staurosporine
- Apoptosis was quantified using an ELISA that measures cytoplasmic 
histone-bound DNA complexes generated during apoptotic DNA fragmentation. 
As shown in Figure 15 (page 33), Staurosporine induced apoptosis in a dose 
dependent manner in DB 46 cells whereas the DC 4 cells apoptosis increased 
eleven fold for the lowest concentration (0.5pM) and higher concentrations had 
little effect in increasing apoptosis. At the highest concentration used, the 
protection offered by Hsp 27 in DB 46 cells no longer existed, in fact at this 
concentration DB 46 cells had higher apoptosis than DC 4 cells. This result is 
important therapeutically, as it tells us that higher concentrations o f the drug may 
be used to treat patients having Hsp 27 positive tumors. Figure 16 (page 34) 
shows the effect o f the drug on DB 26 and DC 7 cell lines. However, DC 7 
(which is similar to DC 4) shows a dose response at all concentrations of the drug 
used. At all concentrations o f the drug used DB 26 cells exhibited lower 
apoptosis than the control transfected cells DC 7. The dramatic sensitivity seen in 
DC 4 cells at lower concentrations o f the drug (11 fold increase in apoptosis at 0.5
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|iM) was not seen in DC 7 ceils (only 4 fold increase in apoptosis at 0.5 pM). 
Such differences may be attributed to clonogenic variations.
Growth Inhibition by Vitamin E Succinate
Vitamin E Succinate (RRR-a-tocopheryl succinate) is the succinate ester 
o f Vitamin E. The succinate ester has been demonstrated to be a potent inhibitor 
of human breast cancer cell proliferation (36). The exact mechanism by which 
Vitamin E Succinate (VES) inhibits proliferation is not known, but cell cycle 
blockages, cellular differentiation, activation o f transforming growth factor-}) and 
induction o f  apoptosis is seen in VES treated cells. VES is mainly attractive for 
its non-toxic effect on normal cell types. Since a lot o f recent work has focused 
on the anti-tumor effect of VES in breast cancer cells, we were interested in 
knowing whether VES could exhibit the same effect or activity in Hsp 27 
expressing breast cancer cells. In this study, we exposed Hsp 27 expressing and 
control transfected cell lines to various concentrations o f VES continuously for 
48-65 h. After 48 h o f incubation, 90%-93% growth inhibition was seen at 
40pg/ml o f VES (Figure 17, page 35). When cells were exposed to 5pg/ml - 
30 pg/ml o f  VES for 65 h (Figure 18, page 36 and Figure 19, page 37), they 
showed a similar response. The highest growth inhibition seen for all four cell 
lines was at 15 pg/ml. At all concentrations, however, Hsp 27 expressing cell 
lines had higher tolerance for the drug than the control transfected cell lines. The
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growth inhibition at various concentrations was normalized to a control, which 
had succinic acid at the same concentration as the highest concentration o f VES 
used. At 65h, the growth inhibition seen in the presence o f VES was higher than 
the growth inhibition seen for the same concentrations at 48 h.
Growth Inhibition by Cycloheximide
Cycloheximide is an antibiotic that inhibits protein biosynthesis. The 
exact mechanism as to how the inhibition of protein synthesis turns on the 
apoptotic cascade is not known. An explanation that has been put forward is that 
Cycloheximide blocks the synthesis o f inhibitor proteins that regulate the 
endogenous endonucleases (37). When the levels o f the inhibitor proteins fall, the 
endonucleases are activated and apoptosis follows. It has also been reported that 
some cells are programmed to die in the absence o f inhibitor proteins (38). In our 
study, the effect o f Hsp 27 on growth inhibition induced by Cycloheximide was 
studied using the MTT assay. Human breast cancer cells that constitutively 
express Hsp 27 and their control transfected counterparts were treated with 
25pM-200pM o f Cycloheximide for a period o f two hours and then allowed to 
grow for 24h-65h. Figure 20 (page 38) and Figure 21 (page 39) shows the 
percentage growth o f cells 24h after the Cycloheximide treatment. The growth in 
both cases was normalized to a control that was treated with 0.1%v/v with 
ethanol. The cells that expressed Hsp 27 showed a higher percentage o f growth 
than the control transfected cell lines at all concentrations of the drug studied.
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The error bars were the percent deviation from the mean o f the experiment set in 
triplicate. Figure 22 (page 40) and Figure 23 (page 41) show the effect o f two- 
hour pulse o f Cycloheximide studied after 65 h. The DB 26 cells (Figure 23) did 
not show a significantly higher growth when compared to the control transfected 
DC 7 cells. In all other cases, (Figures 20-22) Hsp 27 expressing breast cancer 
cells had a higher resistance to the drug than their control transfected 
counterparts.
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Figure 7 Percentage growth o f DB 46 and DC 4 cells 48h after treatment 
with butyrate. The error bars represent percent deviation from 
mean (n=3). (•: p<0.05). OD for untreated controls: (DB 46: 0.461 
and DC 4: 0.451)
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Figure 8 Percentage growth o f DB 26 and DC 7 cells 48h after treatment 
with butyrate. O.D. for untreated controls: (DB 26: 0.474 and 
DC 7: 0.347). (*:p=0.05)
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Figure 9 Percentage growth o f DB 46 and DC 4 cells 24h after treatment 
with butyrate. The error bars represent percent deviation from 
mean (n=3). (• : p=0.05). O.D. for untreated controls: (DB 46: 
0.334 and DC 4: 0..275)
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Figure 10 Percentage growth of DB 26 and DC 7 cells 24h after treatment 
with butyrate. The error bars represent percent deviation from 
mean (n=3). (• : p<0.05). O.D. for untreated controls: (DB 26: 
0.305 and DC 4: 0..254)
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Figure 11 Fold increase in apoptosis o f DB 46 and DC 4 cells 20h after 
treatment with butyrate. The error bars represent standard 
deviation from mean (n=3). (• : p<=0.05). O.D. for serum 
control:0.364
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Figure 12 Fold increase in apoptosis o f DB 26 and DC 7 cells 24h after 
treatment with butyrate. The error bars represent standard 
deviation from mean (n=3). (• : p = 0.05). O.D. for serum 
control;0.313
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Figure 13 Percentage growth o f DB 46 and DC 4 cells 24h after treatment
with Staurosporine. The error bars represent percent deviation 
from mean (n=3). (♦ too few data values to determine statistical 
significance). O.D. for untreated controls:(DB 46: 0.272 and DC 4: 
0.288)
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Figure 14 Percentage growth o f DB 26 and DC 7 cells 24h after treatment 
with Staurosporine. The error bars represent percent deviation 
from mean (n=3). (, : p <=0.05). O.D. for untreated controls:(DB 
26; 0.278 and DC 7; 0.214)
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Figure 15 Fold increase in apoptosis o f DB 46 and DC 4 cells 24h after
treatment with Staurosporine. The error bars represent standard 
deviation from mean (n=3). (• : p <= 0.05). O.D. for serum 
control: 0.240
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Figure 16 Fold increase in apoptosis of DB 26 and DC 7 cells 24h after
treatment with Staurosporine. The error bars represent standard 
deviation from mean (n=3). O.D. for serum control: 0.240
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Figure 17 Percentage growth o f  DB 46 and DC 4 cells 48 h after treatment 
with VES. The error bars represent percent deviation from mean 
(n=3). (.: p=0.05). O.D. for untreated controls:(DB 46: 0.407 and 
DC 4: 0.325)
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Figure 18 Percentage growth of DB 46 and DC 4 cells 65h after treatment 
with VES. The error bars represent percent deviation from mean 
(n=3). (• : p <=0.05). O.D. for untreated controls:(DB 46: 0.609 
and DC 4: 0.551)
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Figure 19 Percentage growth o f DB 26 and DC 7 cells 65h after treatment 
with VES. The error bars represent percent deviation from mean 
(n=3). (* : p <=0.05). O.D. for untreated controls:(DB 26: 0.638 
and DC 4: 0.498)
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Figure 20 Percentage growth o f DB 46 and DC 4 cells 24h after a 2 hour 
treatment with Cycloheximide. The error bars represent percent 
deviation from mean (n=3). (♦ ; p<=0.05). O.D. for untreated 
controls:(DB 46: 0.184 and DC 4: 0.202)
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Figure 21 Percentage growth of DB 26 and DC 7 cells 24h after a 2 hour 
treatment with Cycloheximide. The error bars represent percent 
deviation from mean (n=3). (• : p < = 0.05). O.D. for untreated 
controls:(DB 26: 0.225 and DC 7: 0.461)
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Figure 22 Percentage growth of DB 46 and DC 4 cells 65h after a 2 hour 
treatment with Cycloheximide. The error bars represent percent 
deviation from mean (n=3). (• : p <= 0.05). O.D. for untreated 
controls:(DB 46: 0.426 and DC 4: 0.511)
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Figure 23 Percentage growth of DB 26 and DC 7 cells 65h after a 2 hour 
treatment with Cycloheximide. The error bars represent percent 
deviation from mean (n=3). (• : p < 0.01). O.D. for untreated 
controls:(DB 26; 0.631 and DC 7: 0.473)
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CHAPTER4 
DISCUSSION
Hsp 27 protects the cells from stresses such as heat shock and 
chemotherapeutic agents (15-17). This study focuses on yet another aspect o f  the 
protection offered by this protein - its ability to inhibit programmed cell death or 
apoptosis. It has been reported that the presence o f Hsp 27 in breast cancer cells 
has correlated to a shorter disease free survival and as a marker for more 
aggressive tumors (19). In order to understand the extent o f protection offered by 
Hsp 27 against various cytotoxic drugs, we used human breast cancer cells that 
constitutively express Hsp 27. These cells were constructed from the estrogen 
receptor negative human breast cancer cell line MDA-MB-231 which expresses 
very low endogenous levels o f Hsp 27. MDA-MB-231 cells were transfected 
with the constitutive expression vector pP27 containing the human Hsp 27 cDNA 
sequence or with a control vector pHpApr-l-neo lacking the cDNA sequence 
(21). The constitutive expression o f Hsp 27 has been reported to protect breast 
cancer cells from heat induced cytotoxicity and also decrease the time required to 
resume protein synthesis (17). Others have reported a similar finding using 
different cell lines.
42
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One o f the methods that Hsp 27 may confer protection is by inhibiting cell 
death -  either necrosis or apoptosis. Since many o f the chemotherapeutic drugs 
work by inducing apoptosis, we treated our cells with various cytotoxic drugs 
which have been reported to induce apoptosis in other cell lines, to see whether 
Hsp 27 could offset the drug’s effect. We measured the growth inhibition caused 
by the drug, at first, as an inexpensive indicator o f apoptosis and later measured 
apoptosis induced in some o f the systems using an ELISA. The significance o f 
the data obtained was measured using a t-test (Appendix).
In some cases studied, breast cancer cells expressing Hsp 27 had a higher 
growth in the presence o f the cytotoxic drugs. Each of the drugs chosen induced 
apoptosis in other cell lines by different mechanisms (Figure 24, page 52). In 
order to have a fair understanding o f the point(s) at which Hsp 27 may be acting 
in the apoptotic cascade to inhibit the onset o f apoptosis, I wish to treat each drug 
separately.
Hsp 27 Confers Resistance against Butyrate Induced Apoptosis
Sodium Butyrate is a dietary micronutrient produced by the microbial 
fermentation o f fiber. Sodium Butyrate and other short chain fatty acids have 
been reported to induce growth arrest, differentiation and apoptosis in colonic 
cancer and breast cancer cell lines (25-30). The exact mechanism o f butyrate 
induced apoptosis and growth arrest is not yet known. It has been reported that
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butyrate’s action is tightly linked to mitochondrial function (27,28). Inhibition of 
mitochondrial function, by using inhibitors that blocked the mitochondrial 
electron transport, oxidative phosphorylation and cytochrome c, within 8h of 
butyrate treatment decreased butyrate induced apoptosis in colonic cancer cells 
(28). The growth arrest occurs simultaneously at the Go-Gi and Ga-M o f the cell 
cycle in colonic cancer cells. Breast cancer cells, irrespective of their steroid 
receptor profiles, were blocked at the Ga-M phase o f  the cell cycle (29). In the 
same study by Coradini et al. however, only estrogen receptor positive MCF 7 
and T47D underwent apoptosis in the presence o f  butyrate as detected by gel 
electrophoresis. We observe that the estrogen receptor negative breast cancer 
cells also undergo apoptosis within 24h o f treatment with Sodium Butyrate. The 
difference in the results may be because o f  the method used in detecting 
apoptosis. We used the ELISA system that measures the cytoplasmic histone 
bound DNA fragments generated during apoptosis, a method that may detect 
DNA fragmentation even when the classic ladder pattern is not seen on the 
agarose gel. It has also been reported that butyrate functions as an apoptotic 
inducer by blocking histone deacetylase in Jurkat lymphoid, colorectal and colon 
cancer cells (26, 27). When the function o f histone deacetylase is inhibited, 
histone (H4) is hyperacetylated leading to a more open chromatin structure, which 
opens up the linker regions to endogeneous endonucleases (27). Apoptosis 
induced in these cell lines is strictly dependent on protein synthesis and activation 
o f caspase 3 and is dependent on a cytochrome c dependent pathway Q.1) (see
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page 52). The effect o f butyrate induced apoptosis is regulated by Bcl-2, a 
protein that inhibits apoptosis by inhibiting the transport o f cytochrome c from 
mitochondria to the cytosol (25).
In our study, we observe that human breast cancer cells that express Hsp 
27 underwent less apoptosis in the presence o f butyrate. Since butyrate functions 
at the level o f mitochondria, Hsp 27 may be functioning at the same level or 
downstream o f mitochondria to offset the effect o f  Sodium Butyrate.
Since induction o f  apoptosis by butyrate is dependent on cytochrome c dependent 
pathway which is blocked by bcl-2, it might be interesting to look at whether Hsp 
27 has any effect on the release o f cytochrome c from the mitochondria.
Hsp 27 Confers Resistance against Staurosporine
Staurosporine, a microbial alkaloid is an inhibitor o f a wide range of 
protein kinases including protein kinase C, cyclin dependent kinases(cdks), cyclic 
AMP dependent kinases and p60 v-src protein tyrosine kinase. Protein kinases 
regulate an array o f functions, one o f which is progression through cell cycle by a 
family of cdks. The exact function o f protein kinase C (PKC) has been addressed 
previously {see page 20). It has been reported that Staurosporine causes growth 
arrest at the Gi phase o f the cell cycle in breast cancer cells and HeLa cells (33). 
The growth arrest has been reported to result from an induction o f p21 protein and 
also due to the loss in catalytic activity of the cdks (33,39). p21 is a potent
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inhibitor o f cdks and associates with various cyclin-cdk complexes to inhibit the 
kinase activity o f these complexes. Staurosporine and its analogues have been 
reported to alter the cellular localization o f certain PKC isoforms and inhibit their 
activity (32,35). Staurosporine and its hydroxy derivative, however, have been 
known to activate one o f the PKC isoforms, the PKC a . This activation has been 
reported to occur downstream from caspases in myeloid leukemia cells as 
inhibitors o f caspases blocked the activation o f PKC a  (35). In other studies, with 
cardiomyocytes, it was found that Staurosporine activates caspase 3. This 
activation o f caspase 3 may be upstream o f the activation o f PKC a . It has also 
been reported that caspase 3 cleaves PKC Ô and that this is responsible for the 
morphological features associated with apoptosis (40).
In our study, estrogen receptor negative breast cancer cells that 
constitutively express Hsp 27 lower apoptosis than the control transfected cell 
lines (Figure 15). At the highest concentration o f Staurosporine used however, 
the protection was not observed. This may be because 5pM Staurosporine is 
highly cytotoxic and offsets the protection offered by Hsp 27. Constitutive 
expression o f Hsp 27 also confers resistance to apoptotic cell death induced by 
Staurosporine in murine L929 cells. Ongoing research in our labs indicate that 
Hsp 27 expressing breast cancer cells exhibit lower caspase 3 activity in the first 
8h o f treatment with cytotoxic drugs than the control transfected cell lines (Joe 
Stafford, personal communications). This suggests that Hsp 27 may be conferring 
resistance to Staurosporine by blocking the activation o f caspase 3. Higher
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concentrations or longer incubation times with the dmg may abrogate this effect 
as caspase 3 showed peak activity after 24h o f incubation with cytotoxic drugs.
Hsp 27 Confers Resistance against Vitamin E Succinate
Vitamin E Succinate has been studied widely for its ability to induce 
growth arrest and apoptosis in a variety o f cell lines. The exact mechanism by 
which VES induces apoptosis is not fully known. Recent reports on the effect of 
VES in breast cancer cells have shown that VES enhances the expression of 
transforming growth factor-)) (TGF-P) and its isoforms (36,41,42). TGF-P and its 
isoforms form a family o f growth factors that inhibit the proliferation of 
epithelial, lymphoid and endothelial cells. Malignant transformation has been 
thought to occur when cells escape the growth-inhibitory effects o f TGF-P by 
either inactivation o f  the genes encoding for the factor or its receptor. 
Compounds that stimulate the TGF-P have included retinoids, deltanoids 
(Vitamin D and its analogues), tamoxifen (antiestrogen) and gestodene (synthetic 
progestin)(36). Recently, VES has been added to the list o f these terpene 
compounds that can stimulate TGF-P (42). It has also been reported that VES 
elevates the levels of c-jun (mRNA and protein) and enhances activator protein -1 
(AP-1) binding in a variety o f cell lines (42). c-jun is an important member in the 
AP-I transcription factor family that has been implicated in cell proliferation, 
differentiation, transformation and recently in apoptosis. c-jun can be transiently
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activated by growth factors to increase proliferation in cells.
c-jun is activated by the growth factors through the JNK pathway (Jun N 
terminal kinase) also knovm as the SAPK (stress activated protein kinase) 
pathway to cause an increase in proliferation. When JNK is triggered by 
apoptotic inducers it turns on c-jun by phosphorylation at its serine residue and 
causes cell death via apoptosis. How the same signaling mechanism causes 
opposing fates in cells is unknown. One theory is that sustained JNK activation 
(as seen in the case o f apoptotic inducers) induces apoptosis while transient 
activation (as seen in the case of growth factors) induces proliferation(42).
We observed growth inhibition in breast cancer cells in the presence o f 
VES. The growth inhibition seen in the case o f Hsp 27 expressing cells was 
higher than that seen in the non Hsp 27 expressing cells. Apoptosis was measured 
at 48h and 65h by an ELISA (data not shown) A significant induction in 
apoptosis was not seen at times and concentrations o f the drug used.
Hsp 27 Confers Resistance against Cycloheximide
Cycloheximide also known as actidone is a glutarimide antibiotic that 
inhibits protein synthesis in systems that use 80S ribosomes (43). Cycloheximide 
has been know to induce apoptosis in human breast cancer cells (37). Apoptosis 
is caused in these cells by the inhibition o f protein synthesis. Apoptosis may be 
turned on when the inhibitor proteins that regulate endonucleases are not
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produced in sufficient amounts due to blocked protein synthesis. Cycloheximide 
has also been reported to interfere with glucose transport which in turn influences 
cell death. The exact nature of this effect is not yet elucidated. Contrary to its 
pro-apoptotic function, Cycloheximide has been recently reported to inhibit 
apoptosis in systems that require new protein synthesis to activate caspases (44). 
This discrepancy in its function is still not understood.
In human breast cancer cells, Cycloheximide induces a growth inhibition 
at all concentrations used. However, cells expressing Hsp 27 were able to better 
survive at all concentration of the drug than the control transfected counterparts. 
Apoptosis was measured using ELISA at 48 h and 65h, but no induction of 
apoptosis was seen at the times and concentrations o f the drug used (data not 
shown).
Conclusions
We report that Hsp 27 when present in human breast cancer cells protects 
these cells from a variety o f  cytotoxic inducers acting at different points o f the 
apoptotic pathway (see Table \,p a g e  5J). Constitutive expression o f Hsp 27 has 
been reported to protect murine cells from Fas/APO-1 induced apoptosis, U937 
and Wehi-s cells from camptothecin, etoposide and actinomycin D and human 
breast cancer cells from heat shock (4,5,21). Since Hsp 27 can protect different 
cells from a variety o f stresses that induces apoptosis, it might be acting
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downstream from these inducers or may be acting at different points in the 
apoptotic pathway. It has also been reported that Hsp 27 expression decreased 
intracellular -  reactive oxygen species and increase the cellular content of the 
antioxidant glutathione(4). The presence o f the antioxidant glutathione appears to 
be essential for the protective activity against TNF a  and oxidative stress induced 
cell death. The stimulation o f anti-oxidants may be the way in which Hsp 27 
protects cells from apoptosis. It has also been reported that Hsp 27 is an actin cap 
binding protein(45). Actin is one o f the substrates cleaved by caspases when 
apoptosis is turned on. Protection of actin from caspases may be responsible for 
the anti-apoptotic function o f Hsp 27. A clear knowledge o f the role o f Hsp 27 is 
not known, the knowledge o f its function and the point(s) at which it acts would 
be crucial in developing adjuvant therapies that target this protein in cancer cells.
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Table 1 Summary o f Results
Cell lines Drug Time (h) Results"
Growth Apoptosis
DB 46 & DC 4 NAB 48 h
X
DB 26 & DC 7 NAB 48 h :
DB 46 & DC 4 NAB 24 h ❖
X
DB 26 & DC 7 NAB 24 h »:♦ :
DB 46 & DC 4 STR 24 h ♦
X
DB 26 & DC 7 STR 24 h ♦ El
DB 46 & DC 4 VES 48 h ❖ O
DB 46 & DC 4 VES 65 h
H
O
DB 26 & DC 7 VES 65 h
X
o
DB 46 & DC 4 CHX 24 h
X
DB 26 & DC 7 CHX 24 h
X
DB 46 & DC 4 CHX 65 h
X
o
DB 26 & DC 7 CHX 65 h ❖ o
{K: Significant difference seen in growth between the two cell lines at all 
concentrations, ❖: differences between the two cell lines significant only at 
certain concentrations, ♦ ; too few data values to evaluate the statistical 
significance, E l: no significant differences between cells, O : apoptosis not 
induced at the times and concentration studied, NAB: butyrate, STR: 
Staurosporine, VES: Vitamin E Succinate, CHX: Cycloheximide}
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APPENDIX
CALCULATION OF STATISTICAL SIGNIFICANCE
In order to determine the statistical significance between the growth rates 
and apoptosis o f the DB cell lines (which constitutively express Hsp 27 ) and DC 
cell lines (which lack the constitutive expression vector), the student's t-test is 
used. The student's t-test is generally used to test the hypotheses for mean 
difference between a set o f paired experimental results. In this study all the cell 
lines were derived from estrogen receptor negative MDA-MB-231 human breast 
cancer cells. The only difference between the DB cells lines and the DC cell lines 
is the presence o f Hsp 27 cDNA sequence. Hence we considered the DB cell 
lines and DC cell lines as two sets o f samples and any significant difference 
between their growth rates and apoptosis is attributed to the presence o f Hsp 27 in 
DB cell lines.
This statistical hypotheses is tested assuming normality in the data values 
and the two mean values are independent from each other with unknown and 
equal variances. The equation used is given below;
53
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<»
+  —
where
«, = number of observations comprising the first average x,
«: = number of observations comprising the second average x. 
Sp= pooled standard deviation o f  the standard deviations s, and 
s, for the first and second sets o f data
(«I -  l)j,- + («2 -1)^2
The t value obtained from this calculation is compared with the tp given in 
Table 4, Appendix III {Introduction to Probability and Statistics, by Mendenhall 
and Beaver, 1990). The p  value determines the significance level. If the t value 
exceeded the tp value, then the hypotheses is rejected because the mean values of 
the two samples are significantly different at p  value specified.
In our study, the growth rates o f  the DB and DC cell lines in the presence o f the 
drug is normalized to an untreated control before performing the t-test. This 
normalization prevents the differences (growth rates, survival etc., ) between the 
cell lines from affecting the results seen.
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Sample Calculation
A sample calculation is presented to demonstrate the methodology 
adopted for calculating the statistical significance o f the experimental data. The 
primary objective for using the t-test was to determine if  Hsp 27 expressing cell 
lines were significantly different from control transfected cell lines in their 
response to various drugs. The results from the following example is presented in 
Figure 7.
DB 46 is the Hsp 27 expressing breast cancer cell line and DC 4 is the Control 
transfected cell line. The following data is the O.D. values as measured by the 
plate reader. The average, standard deviation (SD), % deviation (% SD) and % 
growth (%G) were calculated manually.
DB 46 
control
DC 4 
control
DB 46 ImM DC 4 ImM
0.416 0.414 0.401 0.363
Raw data as 
read by the 
plate reader
0.483 0.452 0.424 0.332
0.489 0.476 0.437 0.347
0.455 0.463 0.432 0.350
0.461 0.451 0.424 0.348 Average
0.033 0.027 0.016 0.013 SD
100.00 100.00 91.86 77.16 % G
7.230 5.917 3.761 3.657 % SD
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Calculation o f % Growth and % Deviation
The growth o f untreated controls was set to a hundred percent and all the drug 
treated cells were normalized to this control, 
i.e..
For DB 46 cells, the untreated control had an average O.D. o f 0.461. 
Growth was measured by the MTT assay where the sample O.D. corresponds to 
amount o f living cells. Hence O.D. o f 0.461 was set to 100% growth and drug 
treated DB 46 cells were compared to this control.
For DC 4 cells, the untreated control had an O.D. o f 0.451 which was set 
to 100%. The drug treated DC 4 cells were normalized using this value.
Therefore,
% growth of DB 46 cells in the presence o f ImM Sodium Butyrate is: 
((0.424/0.461)* 100)=91.86
Similarly, % growth o f DC 4 cells in the presence of ImM Sodium Butyrate is: 
((0.348/0.451)*100)=77.16
The percent deviation was calculated using the following equation 
% SD = (Standard deviation/Average)* 100
All other data points in Figure 7 and all other figures have been treated in the 
same fashion.
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Calculation o f t
t was calculated using equations (1) and (2). Taking the same example, as before.
Raw Data Normalized data
DB46 cont. DC4 cont. DB 46 ImM DC 4 ImM DB 46 ImM DC 4 ImM
0.416 0.414 0.401 0.363 0.870 0.805
0.483 0.452 0.424 0.332 0.920 0.736
0.489 0.476 0.437 0.347 0.948 0.769
0.455 0.463 0.432 0.350 0.937 0.776
Average
0.461 0.451 0.919 0.772
Standarc Deviation
0.033 0.027 0.035 0.028
Number o f degrees o f freedom (nl and n2)
4.00 4.00
’ooled standard deviation >p)
0.030
t
6.592
As described previously, the drug treated cells o f each cell line was 
normalized to its respective untreated controls. The t test was performed on the
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normalized data values and not the raw data. The calculated value of t was 
compared to accepted values o f t at 90%-99% confidence levels. If the calculated 
value o f t was greater than accepted values o f t at the confidence levels used, the 
averages (of the cell lines compared) were significantly different from each other.
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